Expertise in
20
conditions

Dr. Sumithira Vasu

Hematology
The Osuccc-James
460 W 10th Ave, 
Columbus, OH 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
19 Years of Experience
Expertise in
20
conditions
The Osuccc-James
460 W 10th Ave, 
Columbus, OH 

Overview

Sumithira Vasu is a Hematologist practicing medicine in Columbus, Ohio. She has been practicing medicine for over 19 years.

Dr. Vasu is highly rated in 20 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Leukemia, Bone Marrow Transplant, and Islet Cell Transplantation.

She is actively involved in clinical research, co-authoring 142 peer reviewed articles and participating in 10 clinical trials. Dr. Vasu is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in OH

Hospital Affiliations

Ohio State University State Health System

Languages Spoken

English
Tamil

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 8 Less Insurance Carriers -

Locations

The Osuccc-James
460 W 10th Ave, Columbus, OH 43210

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Pilot Study of Haploidentical or Matched Donor Virus-Specific T-cells (Cytomegalovirus (CMV) or Adenovirus (AdV)) to Treat CMV or AdV Reactivation or Disease in Patients After Solid Organ or Hematopoietic Stem Cell Transplantation (HCT)
Pilot Study of Haploidentical or Matched Donor Virus-Specific T-cells (Cytomegalovirus (CMV) or Adenovirus (AdV)) to Treat CMV or AdV Reactivation or Disease in Patients After Solid Organ or Hematopoietic Stem Cell Transplantation (HCT)
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Biological
Study Phase: Early Phase 1
Phase II Study of Maintenance Ruxolitinib After Allogeneic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Complete Remission
Phase II Study of Maintenance Ruxolitinib After Allogeneic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) in Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: March 27, 2026
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-shelf, Third-party Natural Killer Cells (KDS-1001) for the Induction of Relapsed/Refractory Acute Myeloid Leukemia
A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-shelf, Third-party Natural Killer Cells (KDS-1001) for the Induction of Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: January 09, 2026
Intervention Type: Biological, Drug
Study Drugs: Cytarabine, Cytarabine Hydrochloride, Decitabine, Fludarabine, Fludarabine Phosphate, Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
Study Phase: Phase 1
Phase I/II Clinical Trial of Daratumumab and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia Post-Allogeneic Hematopoietic Stem Cell Transplant
Phase I/II Clinical Trial of Daratumumab and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia Post-Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: May 21, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Daratumumab
Study Phase: Phase 1/Phase 2
Tagraxofusp in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Tagraxofusp in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Enrollment Status: Completed
Publish Date: August 01, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
Enrollment Status: Unknown
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-001 T Cell Infusion
Study Phase: Phase 1/Phase 2
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: February 04, 2021
A Multi-Center, Phase II Cross-sectional Study Investigating Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: a Companion Study to the CIBMTR 10-CMSMDS-1-Approved Expanded Access Study
A Multi-Center, Phase II Cross-sectional Study Investigating Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: a Companion Study to the CIBMTR 10-CMSMDS-1-Approved Expanded Access Study
Enrollment Status: Completed
Publish Date: December 02, 2020
Intervention Type: Behavioral
Phase I Study of Decitabine and Haplo-identical Natural Killer Cells in Acute Myeloid Leukemia (AML)
Phase I Study of Decitabine and Haplo-identical Natural Killer Cells in Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: March 09, 2020
Intervention Type: Other, Drug, Biological
Study Phase: Phase 1
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: May 09, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

142 Total Publications

Reduced-Dose Post-Transplant Cyclophosphamide (PTCy 40-40) in Allogeneic Hematopoietic Cell Transplantation.
Reduced-Dose Post-Transplant Cyclophosphamide (PTCy 40-40) in Allogeneic Hematopoietic Cell Transplantation.
Journal: Transplantation and cellular therapy
Published: May 26, 2026
Similar Doctors
Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

The James Outpatient Care

2121 Kenny Rd, 
Columbus, OH 
 (0.7 miles away)
800-293-5066
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kami Maddocks is a Hematologist practicing medicine in Columbus, Ohio. Dr. Maddocks is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Maddocks is currently accepting new patients.

Expertise in
28
conditions
Expertise in
28
conditions
Referral may be required

Office

181 Taylor Ave Fl 13, 
Columbus, OH 
 (3.1 miles away)
614-293-9441
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Spero Cataland is a Hematologist practicing medicine in Columbus, Ohio. Dr. Cataland is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Atypical Hemolytic Uremic Syndrome (aHUS), Hemolytic-Uremic Syndrome, D-Plus Hemolytic Uremic Syndrome, and Splenectomy. Dr. Cataland is currently accepting new patients.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

Select Specialty Hosp-Columbus

410 W 10th Ave, 
Columbus, OH 
 (0.1 miles away)
614-293-7677
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jennifer Woyach is a Hematologist practicing medicine in Columbus, Ohio. Dr. Woyach is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Leukemia, and Bone Marrow Aspiration. Dr. Woyach is currently accepting new patients.

Frequently Asked Questions about Dr. Sumithira Vasu

How do I make an appointment with Dr. Sumithira Vasu?

You can book an appointment with Dr. Sumithira Vasu by calling their office at 614-293-3316. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sumithira Vasu a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sumithira Vasu is classified as an Elite expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sumithira Vasu specialize in?

While Dr. Sumithira Vasu is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), and Leukemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Sumithira Vasu participate in research or clinical trials?

Yes. Dr. Sumithira Vasu has published 142 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Sumithira Vasu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sumithira Vasu accept my insurance?

Dr. Sumithira Vasu accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 614-293-3316 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vasu's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 10 Advanced Conditions
View All 39 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile